Transcriptomic responses to prion disease in rats by unknown
RESEARCH ARTICLE Open Access
Transcriptomic responses to prion disease
in rats
Allen Herbst1, Anthony Ness2, Chad J. Johnson3, Debbie McKenzie2 and Judd M. Aiken1*
Abstract
Background: Prions diseases are fatal neurodegenerative diseases of mammals. While the molecular responses to
prion infection have been extensively characterized in the laboratory mouse, little is known in other rodents. To
explore these responses and make comparisons, we generated a prion disease in the laboratory rat by successive
passage beginning with mouse RML prions.
Results: We describe the accumulation of rat prions, associated pathology and the transcriptional impact
throughout the disease course. Comparative transcriptional profiling between laboratory mice and rats suggests
that similar molecular and cellular processes are unfolding in response to prion infection. At the level of individual
transcripts, however, variability exists between mice and rats and many genes deregulated by prion infection in
mice are not affected in rats.
Conclusion: Our findings detail the molecular responses to prion disease in the rat and highlight the usefulness of
comparative approaches to understanding neurodegeneration and prion diseases in particular.
Background
Prion diseases are an unusual class of fatal, transmis-
sible, neurodegenerative disorders that affect the mam-
malian central nervous system. They are caused by the
accumulation of an abnormal conformation of the nor-
mal host encoded cellular prion protein, PrPC. Although
the exact mechanism is unknown, this conformational
rearrangement of PrPC is thought to be brought about
by template-directed misfolding wherein seed molecules
of the abnormal isoform, PrPSc, convert PrPC into new
PrPSc molecules. Laboratory investigation of prion dis-
eases typically relies upon rodents, which can be infected
with natural isolates of scrapie [1] albeit with some diffi-
culty as ovid scrapie isolates need time to adapt to ro-
dents. This adaptation is characteristic of interspecies
transmission of prion infections and reflects the molecular
adaptation that must occur to allow interaction between ex-
ogenous foreign PrPSc and host PrPC molecules, selecting
for conformations which exhibit efficient template-directed
prion-specific folding. In some cases, no conformational
solution is found, reflecting a molecular species barrier to
disease transmission.
In recent years, advances in genomic technologies have
allowed unprecedented examination of the transcriptional
responses induced by prion infection. These studies [2–9]
have the aim of identifying pathways underlying the mech-
anism of prion-induced neurotoxicity. A second important
aim has been to identify signature molecules that might
act as surrogate biomarkers for these diseases as there are
significant analytical challenges associated with sensitively
detecting and specifically distinguishing PrPSc from nor-
mal PrPC. This work has most commonly been performed
using laboratory mice as cross-sectional time course ex-
periments can be performed, including the important pre-
clinical asymptomatic phase of disease. Critically, however,
the relevance and generalizability of mouse prion re-
sponses to prion diseases of other species is unknown. To
begin addressing these issues, we adapted mouse RML
prions into rats with the aim of identifying common prion
disease transcriptional responses. Brain tissue from con-
trol and scrapie affected rats was transcriptionally profiled
and genes whose expression was changed in response to
prion diseases identified. We identified 712 genes differen-
tially regulated in rat prion disease. Only 33 % of the rat
genes with changes in expression were found to have
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similar responses in the corresponding mouse orthologs,
questioning the universality of previous mouse gene ex-
pression profiles. This comparative approach allowed the
identification of genes whose prion-induced expression
change is conserved between mice and rats and highlights
the significance of these genes. We show that Rat-Adapted
Scrapie (RAS) is a powerful tool for an -omics based ap-
proach to decipher the molecular impact of prion disease
in vivo, with applicability to the molecular mechanisms of
disease and biomarker discovery.
Results
Development of rat-adapted scrapie
To develop a rat-adapted strain of prion disease, we in-
troduced 6 different prion disease agents, Chandler/
RML from mice, Stetsonville transmissible mink enceph-
alopathy (TME), Hyper from hamsters, skunk-adapted
TME and Chronic Wasting Disease (CWD) from wild
type and 96S deer [1, 10–13] into rats (Fig. 1). Of these
primary transmissions, only RML mouse scrapie induced
the accumulation of proteinase K resistant PrP (PrP-res)
after 1 year of incubation as determined by western ana-
lysis (10 % brain homogenates and phosphotungstic
acid-enriched brain homogenates). Second passage of
rat-adapted RML resulted in clinically affected rats at
565 days post-inoculation (dpi). Upon subsequent serial
passage, the incubation period stabilized at ~200 days.
Clinical symptoms of prion disease in the rat consisted
of ataxia, lethargy, wasting, kyphosis, and myoclonus.
Prion-affected rats also show porphyrin staining around
their head.
PrP-res was detected in all infected animals by both im-
munoblot (Fig. 2) and immunohistochemistry (Fig. 3). Di-
and mono-glycosylated bands were the most abundant
isoforms of PrPSc (Fig. 2). PrPSc was extensively deposited
in the cerebral cortex, hippocampus, thalamus, inferior
colliculus and granular layer of the cerebellum (Additional
file 1: Figure S1). GFAP-expressing activated astrocytes
were found throughout the brain, particularly in the white
matter of the hippocampus, thalamus and cerebellum
(Additional file 1: Figure S2). Spongiform lesions were a
predominant feature of clinical rat disease (Fig. 3).
Gene expression profiling of rat-adapted scrapie
To define the molecular pathology of rat-adapted scrapie,
gene expression profiling was performed on brain tissue
from infected and age-matched control rats at three time
points. Rat cohorts were sacrificed at two preclinical time
points, 113 and 150 days post-inoculation, as well as dur-
ing clinical disease (198 days). At the clinical disease, 712
genes were differentially regulated within a 95 % confi-
dence interval (Additional file 2: Table S1) and 367 genes
were differentially expressed by greater than 2-fold (Fig. 4).
Significant genes and their orthologs were used for path-
way analysis using DAVID Bioinformatics Resource [14]
(Additional file 3: Table S2, Additional file 1: Figure S3).
Pathway analysis suggested that the gene expression pro-
file was consistent with immune activation and matur-
ation as well as inflammation (Additional file 2: Table S1),
an interpretation supported by the observable GFAP posi-
tive astrocytes (Fig. 3) and gliosis associated with prion
disease. Other pathways highlighted by the analysis in-
clude an increase in the transcripts of lysosomal and
endosomal components. Many genes changes that were
observed at clinical time points were also up-regulated
earlier in disease, during the preclinical stage (Fig. 4b).
Validation of gene expression was performed using
TaqMan qPCR assays (Additional file 1: Figure S4). Data
are deposited in the NCBI GEO repository under the
accession number GSE63930.
Comparative transcriptomics
To further explore the gene expression data, differen-
tially expressed probe sets in rat adapted scrapie were
compared with their mouse orthologs in RML scrapie
and vice versa. Raw mouse gene expression data was
downloaded from prion.systemsbiology.net [6], normalized
Fig. 1 Interspecies transmission of prion disease. Six prion agents
were used for initial transmission to rats including transmissible mink
encephalopathy (TME), skunk-adapted TME, hamster-adapted TME
strain Hyper, Rocky Mountain Laboratories (RML) mouse-adapted
scrapie, chronic wasting disease (CWD) from wild-type deer, and
CWD from wt/96S deer. After 1 year of incubation, first passage rats
were euthanized to determine the extent of PrP-res accumulation.
PrP-res was observed solely in rats infected with RML scrapie prions.
This agent was serially passaged until becoming rat-adapted, as
indicated by the decrease in and stabilization of the incubation
period. Third passage rat-adapted scrapie transmitted to mice and
hamsters with 100 % penetrance
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and analyzed similarly to the rat data. Mouse RML prion
responses at clinical (22 and 23 weeks post- infection) and
two preclinical time points (16 and 18 or 10 and 12 weeks
post-infection) were selected to correspond, fractionally, to
our rat time points, 113, 150 and 198 dpi. A high degree of
correlation between expression fold changes was not ob-
served (Fig. 5). To examine comparative gene expression
responses qualitatively, three approaches were used. In one
strict analysis, gene expression responses from orthologs
with “best match” probe sets (3700 orthologous pairs) were
compared. Of these 3700 probe sets, 22 were deregulated
greater than 2-fold in rat scrapie at clinical disease. Of
these 22, half were also deregulated at least 2-fold in
mouse scrapie. In a broader analysis, 32,625 orthologous
rat-mouse probe sets were identified using Ensembl Bio-
Mart [15, 16]. Of these mouse-rat probe set pairs, 250
were deregulated greater than 2-fold in mouse scrapie at
clinical disease. 149 of the 250 were deregulated greater
than 2-fold in rats. In a final analysis, 333 genes whose ex-
pression is deregulated in mouse prion disease were exam-
ined for their correlation to rat disease. This 333 gene set
is representative of the mouse prion disease transcriptome
and was derived from experiments profiling prion disease
responses in multiple backgrounds of mice, including
transgenically modified mice and multiple strains of
mouse scrapie prions [6]. Assigning and subsequent map-
ping of the 333 mouse genes to rats using Ensembl
BioMart results in 499 probe set pairs, reflecting 288 rat
genes. Of the 499 mouse probe sets whose expression is
changed in response to mouse scrapie, only 317, 234 and
202 rat probe sets are changed greater than 1.5-, 1.8- and
2-fold respectively. We conclude that many genes deregu-
lated in rat scrapie are not differentially expressed in
mouse scrapie and vice versa. For example, cathepsin E is
up-regulated 5.6-fold in rat scrapie, but not differentially
expressed (1.1-fold) in mouse scrapie. Similarly, scrapie re-
sponsive gene 1 [17, 18] was up-regulated 1.6-fold in
mouse scrapie, but not differentially expressed (1.1-fold)
in rat scrapie. Additional file 4: Table S3 includes a refined
list of prion disease responsive transcripts conserved in
rodent scrapie. Despite these differences at the level of
some individual genes, the overall gene expression profiles
were similar. Mapping deregulated genes from both mice
and rats to gene ontology terms identified the same bio-
logical processes. Visualization of these gene ontology
terms and their order of significance using tree mapping
[19] (Additional file 1: Figure S3) demonstrates the overall
similarity between gene expression profiles between mice
and rats.
Discussion
Mice have been the preferred laboratory rodent for prion
diseases research because they can be inexpensively
housed and are amenable to transgenesis, facilitating
Fig. 2 Accumulation of PrP-res in rat-adapted scrapie (RAS). Brain homogenates from each passage were assayed for the presence of protease resistant
PrPPrP-res by immunoblot. PrP-res was observed following phosphotungstic acid (PTA) enrichment at first passage. Di- and mono- glycosylated bands
were the most abundant isoforms of PrP-res. Uninfected age-matched controls are shown for 3rd and 4th passage animals. In fourth passage, PrP-res
accumulated to substantial levels by 117 days post-infection (dpi)
Fig. 3 Histological analysis of rat-adapted scrapie in the hippocampus at clinical disease. Infected animals showed intense immuno-staining for
deposits of PrP-res and GFAP expressing astrocytes. Spongiform change is an abundant feature in rat prion disease. The scale bar represents 250um
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short incubation periods upon over expression of PrP or
examination of non-murine prion replication by exogen-
ous PrP expression. Subsequent to the sequencing and
annotation of the mouse genome and the development
of high density transcriptional arrays for measurements
of gene expression profiling, mice have been used exten-
sively to examine the molecular pathology of prion
disease probing the impact of prion and animal strain. To
expand upon this foundation, we adapted mouse prions to
rats. We reasoned that by taking a comparative approach
to the molecular pathology of prion disease, inferences into
the variability of the molecular response to prion diseases
could be obtained. Finally, rats, like mice, can be used in a
time course study of prion disease. This allows for the
Fig. 4 Gene expression profile from rats clinically affected with prion disease. a. The expression levels of individual genes from uninfected and
rats clinically affected with prion disease were plotted. The axis is the expression level from uninfected rats and the y-axis is the corresponding
expression level of the gene in infected rats. The green lines indicate 2-fold changes in gene expression. Any points outside of these lines are
genes whose expression is deregulated greater than 2-fold. b. Cluster of 81 genes whose expression is up-regulated throughout disease.
Clustering was performed using 291 genes whose expression was changed more than 2-fold and with a statistical confidence interval of 90 %
using a false positive rate approach. Ontological analysis of this gene cluster is consistent with the involvement of these genes in neuroinflammation.
Gene expression profiles were obtained from infected and control rats at three time points. Comparisons between uninfected rats at the three time
points did not identify statistically significant changes in gene expression
Fig. 5 Comparison of genes upregulated in rat and mouse prion disease. a. Orthologous probe sets differentially regulated by 2-fold were identified
in both rat and mouse prion disease and the overlap determined. Duplicate probe sets measuring the same gene were eliminated for simplicity.
b. Mouse scrapie induced gene expression changes were regressed onto changes induced by rat scrapie. Expression values are log2 transformed. The
grey box indicates those orthologs whose expression is not changed >2-fold. Expression of probe sets that lie along the axes are highly divergent in
prion disease between mice and rats. Stricter bioinformatic mapping of orthologous pairs did not meaningfully improve the regression
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identification of early transcriptional responses to prion in-
fection, responses which are particularly valuable for the
identification of surrogate disease biomarkers.
To generate rat prion disease, we attempted to adapt six
different prion disease agents to rats (Fig. 1). Of these six
agents, only mouse RML prions were able to surmount the
molecular species barrier to prion disease transmission.
Mouse PrP differs from the rat by ten amino acid changes,
seven in the mature protein and four in the N-terminal
octa-peptide repeat region (Additional file 1: Figure S5.) As
rat shares the most prion protein sequence identity with
the mouse, is perhaps not surprising that the mouse-
adapted agent transmitted whereas the other prion agents
did not. The lack of transmission of the other agents may
be explained based upon divergent amino acid residues
that inhibit conversion of rat PrPC. For example, at pos-
ition 113, mice and rats share a common leucine whereas
the other prions tested contain methionine.
Our adaptation of mouse scrapie into rats appears
similar to that process observed by Kimberlin and
Walker [20]. The increase in incubation period at second
passage is due to our sacrificing first passage rats at
365 days post-inoculation despite a lack of clinical symp-
toms, whereas Kimberlin and Walker allowed the first
passage animals to reach clinical disease. Slight increases
in reported incubation periods in our experiments com-
pared to the Kimberlin transmission, are due to different
criteria for euthanizing animals; Kimberlin and Walker
sacrificed rodents at the onset of clinical disease. The simi-
larity of our rat-adapted scrapie with the Kimberlin rat
transmission is supported by back passage and interspe-
cies transmission experiments. Back passage of RAS to
mice reestablished a strain that was indistinguishable from
RML/Chandler with an incubation period of 158 days.
Transmission of RAS into hamsters resulted in an incuba-
tion period of 154 days post infection after second pas-
sage. The passage of rat agent into mice and hamsters
bears resemblance to that of Kimberlin and Walker and
supports the conclusion that the two rat prion infections
are similar. By third passage, the rat prions were fully
adapted. Subsequent passages did not result in significant
incubation period shortening and gene expression data
from third passage clincially affected rats is substantially
identical to fourth passage rats.
Rat-adapted scrapie exhibits features common to other
prion diseases. A long preclinical phase precedes a rapid
clinical period marked by a progressive neurological dys-
function with prominent ataxia, kyphosis and wasting.
The protease resistant PrP observed is typical as is the
widespread deposition of PrPSc in the brain. Spongiosis
and reactive astrogliosis are as expected of a prion disease.
Gene expression profiles from rats clinically affected with
prion disease revealed a strong neuronal inflammation as-
sociated with proliferated and activated astrocytes. This is
perhaps best observed through the up-regulation of GFAP,
a hallmark of the molecular response to prion infection.
GFAP was up-regulated 1.7, 2.6 and 3.5 fold at the 2 pre-
clinical and clinical time points in rats.
Strategies comparing gene expression between mice and
rats were undertaken to explore the level of conservation
of prion disease transcriptomic responses. Analysis of
both narrow and broad subsets of genes were undertaken
to remove selection bias. Gene subsets were selected
based upon stringent similarities in oligonucleotide probe
design including identical gene regions in rat and mouse
and high percent identity between orthologous probe
pairs. In many cases, probes were identical. Broader exam-
ination of gene subsets were also undertaken to ascertain,
more globally, the degree of similarity between the tran-
script profiles. Finally, mouse genes whose transcriptional
responses were deregulated across different prion strain
and mouse background combinations and considered cen-
tral to prion disease were examined. Our comparative
analyses of gene expression changes between mouse RML
and rat-adapted scrapie suggest that there are differences
in gene expression in response to prion disease at the level
of individual transcripts, despite the fact that the overall
response is neuro-inflammatory and many processes are
conserved. Immune response processes are the most sig-
nificant gene ontology categories identified in both mice
and rats. This is consistent with the observed neuroin-
flammation that accompanies prion disease progression
and pathogenesis.
One interpretation of the observed differences between
mice and rats could be based upon strain phenomena.
Prion strains result from conformational differences in the
tertiary structures of PrPSc. Different strains of prions have
different biochemical and biological properties, thus they
might also elicit different molecular responses, observable
in transcriptome type experiments. Gene Expression pro-
files of 301 V and RML on the same mouse background,
however, show similar transcriptomic responses to prion
disease [6]. The variations observed in response to differ-
ent prion strains are smaller than those observed between
different strains of mice which are smaller than those ob-
served in different species. Similarly recent comparisons of
22 L and RML mouse prion infections, which affect differ-
ent brain regions, identified strikingly similar gene expres-
sion responses [9]. Further, it is unlikely that evolution
would have selected for distinct molecular neurodegenera-
tive responses to different prion strains. At the whole brain
level, species specific differences seem more important.
Conclusions
In this study, we describe the transmission and adapta-
tion of mouse scrapie prions into rats. Comparative ana-
lysis of gene expression changes in mice and rat prion
disease identified differences in gene expression of the
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level of individual genes, despite the fact that the overall
profile is neuro-inflammatory and conserved. These data
suggest caution in extrapolating solely from mouse prion
gene expression data to prion infections in other species
especially at the level of individual transcripts. Our data
further show the utility of the laboratory rat as a useful
prion disease research tool and demonstrate the power
of comparative transcriptional profiling to explore the
systems biology of prion diseases.
Methods
Ethics statement
This study was carried out in accordance with the rec-
ommendations in the NIH Guide for Care and Use of
Laboratory Animals and the guidelines of the Canadian
Council on Animal Care. The protocols used were ap-
proved by the Institutional Animal Care and Use Com-
mittees at the University of Wisconsin and University
of Alberta.
Rat transmission and adaptation
Prion agents used were the Rocky Mountain Lab (RML)
strain of mouse-adapted scrapie, Stetsonville Transmis-
sible Mink Encephalopathy [10] (TME), Hyper (Hy)
strain of Hamster TME [11], 1st passage Skunk-adapted
TME [12] prepared by transmission of TME into skunks
and CWD from genetically defined deer transmissions
[13]. Six rats were infected with each prion at first and
second passage.
Brains from animals clinically affected with prion disease
were aseptically removed and prepared as 10 % (w/v) ho-
mogenates in sterile water. 10 % brain homogenate (50uL)
was inoculated intracranially into weanling Wistar rats.
After 1 year of incubation, preclinical rats from all infec-
tions were euthanized by CO2 inhalation and the brain ex-
cised, homogenized and analyzed by western blot. PrPSc
positive samples (from the mouse RML transmission) were
re-inoculated into naive animals. Subsequent serial pas-
sages were from rats clinically affected with rat-adapted
scrapie.
Brains from rat passages were aseptically removed and
bisected sagitally. Brain halves were reserved for immu-
nohistochemistry (IHC) in formalin, or frozen on dry ice
for immunoblotting, RNA isolation or subsequent pas-
sage. For IHC, tissues were fixed in 10 % buffered for-
malin, followed by antigen retrieval at 121C, 210 KPa in
10 mM citrate buffer for 2 min. After cooling to room
temperature, sections were treated with 88 % formic acid
for 30 min and 4 M guanidine thiocyanate for 2 h. En-
dogenous peroxidases were inactivated by 0.03 % hydro-
gen peroxide and tissue was blocked with 1 % normal
mouse serum. Mouse anti-PrP mAB SAF83 (Cayman
Chemical) was biotinylated and applied at a 1:250 dilu-
tion in blocking buffer overnight at 4C. Washes were
performed in 10 mM PBS with 0.05 % Tween-20.
Streptavidin-peroxidase (Invitrogen) was added for DAB
color reaction. Anti-GFAP immunohistochemistry was
performed as above but with the formic acid and guan-
idine treatment steps excluded. Mouse anti-GFAP mab
G-A-5 (Sigma), was used at a 1:400 dilution.
Brain samples for immunoblot were treated with or with-
out Proteinase K (Roche) at a ratio of 3.5ug PK/100ug pro-
tein at 50ug/mL for 30 min at 37C. Phosphotungstenic
acid enrichments were performed as described [21, 22].
Bis-Tris SDS-PAGE was performed on 12 % polyacryl-
amide gels (Invitrogen) and transferred to PVDF. Immuno-
blotting was performed using mABs SAF83 (Cayman
Chemical), 6H4 (Prionics), or 3 F10 (a kind gift from
Yong-Sun Kim), all at a 1:20,000 dilution.
Gene expression profiling
RNA was extracted from frozen brain halves from infected
and control animals with the QIAshredder and RNeasy
mini kit (Qiagen, Valencia, CA) in accordance with the
manufacturer’s recommendations. Due to the relatively
large mass of rat brain, an initial homogenization was per-
formed with a needle and syringe in 5 mL of buffer RLT,
before further diluting an aliquot as per the manufac-
turer’s instructions. RNA was examined using a bioanaly-
zer(Agilent Technologies, Santa Clara, CA) to ensure the
quality of isolated RNA. Total RNA was amplified and la-
beled in preparation for chemical fragmentation and
hybridization with the MessageAmp Premier RNA ampli-
fication and labeling kit (Life Technologies, Grand Island,
NY). Amplified and labeled cRNAs were hybridized on
Affymetrix (Santa Clara, CA) rat genome 230 2.0 high
density oligonucleotide arrays in accordance with the
manufacturer’s recommendations. Three biological repli-
cates were examined from infected and control rats at
clinical disease following third passage and from each time
point (113, 150 and 198 days post infection) of the fourth
passage. Quantitative PCR validation assays were per-
formed on cDNA samples by probe cleavage assays. RNA
samples were normalized to the relative amounts of
GAPDH and β-Actin. Three biological replicates and
three technical replicates were analyzed for each gene and
at each time point.
Data analysis
Differentially Expressed Genes were identified using
Arraystar 5.0 (DNA Star, Madison, WI). Robust multiarray
normalization using the quantile approach was used to
normalize all microarray data. A moderated T-test with a
multiple comparison adjustment [23] was used to reduce
the false discovery rate, yet preserve a meaningful number
of genes for pathway analysis. Pathway analysis was per-
formed using the DAVID Bioinformatics database [14].
Comparative analysis of genes induced by prions in mouse
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[6] and rat disease was performed on probe set matches
generated by the Affymetrix comparison spreadsheets and
matches obtained by using ENSEMBLE biomart release
78 [15, 24].
Availability of supporting data
The data sets supporting the results in this article are
available in the NCBI GEO repository under accession
GSE63930.
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